Skip to main content

Advertisement

SpringerLink
Log in

Ovarian Cancer Stem Cells: Newer Horizons

  • Mini Review Article
  • Published:
The Journal of Obstetrics and Gynecology of India Aims and scope Submit manuscript

Abstracts

The ovarian cancer is one of the frequent cancers among women being diagnosed after cervical and breast cancer. The CA ovary is dreaded because even after successful treatment of the primary malignancy, the disease comes back and becomes resistant to conventional management. The prognosis in ovarian cancer management is mostly unsatisfactory, maybe because of the presence of ovarian cancer stem cells (OCSC). The hypothesis is that OCSC causes the recurrence of the ovarian malignancy. The OCSC can be identified by the presence of different markers and marker combinations. The assumptions are that CD44+, CD24+, CD117+, CD133+ and ALDH1+ could be the markers of ovarian cancer stem cells. The epithelial ovarian malignancy if proved as a stem cell disease, then it changes the entire management scenarios. Maybe, this will be the first step in managing the ovarian malignancy in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ottevanger PB. (2017) Ovarian cancer stem cells more questions than answers. In Seminars in cancer biology;44: 67–71, Jun 1, 2017.

  2. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–25. https://doi.org/10.1038/nrc3144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–79. https://doi.org/10.1038/nrc4019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Terraneo N, Jacob F, Dubrovska A, Grunberg J. Novel therapeutic strategies for ovarian cancer stem cells. Front Oncol. 2020;2020:00319. https://doi.org/10.3389/fonc.2020.00319.

    Article  Google Scholar 

  5. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65(8):3025–9.

    Article  CAS  Google Scholar 

  6. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313–9.

    Article  CAS  Google Scholar 

  7. Bukovsky A, Caudle MR, Svetlikova M, Upadhyaya NB. Origin of germ cells and formation of new primary follicles in adult human ovaries. Reproductiv Biol Endocrinol. 2004;2(1):20.

    Article  Google Scholar 

  8. Clarke-Pearson DL. Screening for ovarian cancer. New Engl J Med. 2009;361(2):170–7.

    Article  CAS  Google Scholar 

  9. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2008;18(3):506–14.

    Article  CAS  Google Scholar 

  10. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28(2):209.

    Article  CAS  Google Scholar 

  11. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311–20.

    Article  CAS  Google Scholar 

  12. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010;9:3186–99.

    Article  CAS  Google Scholar 

  13. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, MacLaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci. 2006;103(30):11154–9.

    Article  CAS  Google Scholar 

  14. Yahata T, Muguruma Y, Yumino S, Sheng Y, Uno T, Matsuzawa H, Ito M, Kato S, Hotta T, Ando K. Quiescent human hematopoietic stem cells in the bone marrow niches organize the hierarchical structure of hematopoiesis. Stem Cells. 2008;26(12):3228–36.

    Article  Google Scholar 

  15. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105.

    Article  CAS  Google Scholar 

  16. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611–29. https://doi.org/10.1038/nrclinonc.2017.44.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Li SS, Ma J, Wong AST. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism. J Gynecol Oncol. 2018;29:e32. https://doi.org/10.3802/jgo.2018.29.e32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bregenzer M, et al. The role of cancer stem cells and mechanical forces in ovarian cancer metastasis. Cancers. 2019;11:1008. https://doi.org/10.3390/cancers11071008.

    Article  CAS  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Institute of Obstetrics and Gynaecology, Sir Ganga Ram Hospital, New Delhi, India

    Mala Srivastava, Neha Ahlawat & Ankita Srivastava

Authors
  1. Mala Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neha Ahlawat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ankita Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mala Srivastava.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Dr. Mala Srivastava is a Professor at GRIPMER, Institute of Obstetrics and Gynaecology, SGRH, N. Delhi; Neha Ahlawat is a Research Assistant with Dr. Mala Srivastava; Dr. Ankita Srivastava is a Clinical Assistant, Institute of Obstetrics and Gynaecology, SGRH, N. Delhi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Srivastava, M., Ahlawat, N. & Srivastava, A. Ovarian Cancer Stem Cells: Newer Horizons. J Obstet Gynecol India 71, 115–117 (2021). https://doi.org/10.1007/s13224-020-01412-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13224-020-01412-7

Keywords

Search

Navigation